Skip to content

Psychopharmacology

ISSN 1432-2072, 0033-3158

637 papers in the library · 20,322 citations · publishing 1971-2026

Papers

Sort Most recent Most cited

Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy.

Psychopharmacology November 21, 2020 Allison A. Feduccia, Lisa Jerome, Michael C Mithoefer et al. 39 citations Retracted

Abstract Rationale MDMA-assisted psychotherapy is under investigation as a novel treatment for posttraumatic stress disorder (PTSD). The primary mechanism of action of MDMA involves the same reuptake transporters targeted by antidepressant medications commonly prescribed for PTSD. Objectives Data were pooled from four phase 2 trials of MDMA-assisted psychotherapy. To explore the effect of...

Uncovering psychological mechanisms mediating the effects of drugs: some issues and comments using the example of psychedelic drugs

Psychopharmacology November 5, 2020 S. Kangaslampi

Researchers have begun efforts to uncover the psychological mechanisms by which psychedelic drugs may have beneficial effects on long-term outcomes in some circumstances. The approaches several recent publications on the topic have taken to analyze such mechanisms have some pitfalls and limitations. Based on the rich literature on mechanisms and mediation analysis in psychological science, I...

Broadening Your Mind to Include Others: The relationship between serotonergic psychedelic experiences and maladaptive narcissism.

Psychopharmacology September 1, 2020 Valerie van Mulukom, Ruairi E Patterson, Michiel van Elk 61 citations

Recent research has shown that classical serotonergic psychedelic (CSP) drugs may be used to ameliorate certain health issues and disorders. Here we hypothesised that CSP experiences, through their ability to induce awe and ego-dissolution, may result in a reduction of maladaptive narcissistic personality traits, such as a strong sense of entitlement and lack of empathy. Our objective was to...

Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.

Psychopharmacology August 1, 2020 Lisa Jerome, Allison A. Feduccia, Julie B. Wang et al. 163 citations Retracted

Posttraumatic stress disorder (PTSD) is a chronic condition that has wide-ranging negative effects on an individual's health and interpersonal relationships. Treatments with long-term benefits are needed to promote the safety and well-being of those suffering from PTSD. To examine long-term change in PTSD symptoms and additional benefits/harms after 3,4-methylenedioxymethamphetamine...

Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan.

Psychopharmacology August 1, 2020 Theresa M. Carbonaro, Matthew W Johnson, Roland R. Griffiths 51 citations

Although both psilocybin and dextromethorphan (DXM) produce psychedelic-like subjective effects, rates of non-medical use of psilocybin are consistently greater than DXM. New data are presented from a study of psilocybin and DXM relevant to understanding the features of psilocybin subjective effects that may account for its higher rates of non-medical use. Single, acute oral doses of psilocybin...

Modulatory effects of ayahuasca on personality structure in a traditional framework

Psychopharmacology July 23, 2020 Nige Netzband, Simon Ruffell, Sabriya Linton et al. 56 citations

Abstract Abstract Ayahuasca is a psychoactive plant brew containing dimethyltryptamine (DMT) and monoamine oxidase inhibitors (MAOIs). It originates from the Amazon basin, where it is used primarily for ceremonial purposes. Ayahuasca tourists are now entering certain communities seeking alternative physical or psychological healing, as well as spiritual growth. Rationale Recent evidence has...

Ayahuasca blocks the reinstatement of methylphenidate-induced conditioned place preference in mice: behavioral and brain Fos expression evaluations

Psychopharmacology July 16, 2020 Henrique Sousa Reis, Isa R S Rodrigues, Alexia Anjos-Santos et al. 21 citations

RationaleAccumulating evidence suggests that ayahuasca, a hallucinogenic beverage used in traditional Amazonian communities for ritualistic and curative purposes, has been associated with reduced rates of substance use disorders. However, the brain mechanisms underlying the therapeutic effects of ayahuasca have not yet been fully elucidated.ObjectivesThe aim of the present study was to...

DOI: 10.1007/s00213-020-05609-6 (opens in new tab) Ayahuasca Methylphenidate Infralimbic cortex Ventral tegmental area +7

Cannabinoid modulation of corticolimbic activation to threat in trauma-exposed adults: a preliminary study.

Psychopharmacology June 2020 Christine A Rabinak, Ashley Blanchette, Nicole L Zabik et al.

Excessive fear and anxiety, coupled with corticolimbic dysfunction, are core features of stress- and trauma-related psychopathology, such as posttraumatic stress disorder (PTSD). Interestingly, low doses of ∆9-tetrahydrocannabinol (THC) can produce anxiolytic effects, reduce threat-related amygdala activation, and enhance functional coupling between the amygdala and medial prefrontal cortex and...

Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys.

Psychopharmacology May 1, 2020 C Austin Zamarripa, Jennifer E Naylor, Sally L Huskinson et al.

Combinations of mu and kappa opioid receptor (KOR) agonists have been proposed as potential analgesic formulations with reduced abuse liability. The current studies extend previous work by investigating the typical KOR agonist, salvinorin A, and the atypical KOR agonist, nalfurafine, as deterrents of oxycodone self-administration using a progressive ratio (PR) schedule of reinforcement. In...

DOI: 10.1007/s00213-020-05473-4 (opens in new tab) Full text (opens in new tab) Kappa opioid agonist Oxycodone Punishment Rhesus monkey +1

Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.

Psychopharmacology May 1, 2020 Toby Lea, Nicole Amada, Henrik Jungaberle et al.

The regular consumption of very small doses of psychedelic drugs (known as microdosing) has been a source of growing media and community attention in recent years. However, there is currently limited clinical and social research evidence on the potential role of microdosing as therapies for mental and substance use disorders. This paper examined subjective experiences of microdosing...

Tripping on nothing: placebo psychedelics and contextual factors

Psychopharmacology March 7, 2020 Jay A. Olson, Léah Suissa-Rocheleau, Michael Lifshitz et al. 148 citations

RationaleIs it possible to have a psychedelic experience from a placebo alone? Most psychedelic studies find few effects in the placebo control group, yet these effects may have been obscured by the study design, setting, or analysis decisions.ObjectiveWe examined individual variation in placebo effects in a naturalistic environment resembling a typical psychedelic party.MethodsThirty-three...

DOI: 10.1007/s00213-020-05464-5 (opens in new tab) Nothing Placebo Tripping Clinical psychology +3

4-MeO-PCP and 3-MeO-PCMo, new dissociative drugs, produce rewarding and reinforcing effects through activation of mesolimbic dopamine pathway and alteration of accumbal CREB, deltaFosB, and BDNF levels.

Psychopharmacology March 1, 2020 Arvie Abiero, Chrislean Jun Botanas, Raly James Custodio et al.

A high number of synthetic dissociative drugs continue to be available through online stores, leading to their misuse. Recent inclusions in this category are 4-MeO-PCP and 3-MeO-PCMo, analogs of phencyclidine. Although the dissociative effects of these drugs and their recreational use have been reported, no studies have investigated their abuse potential. To examine their rewarding and...

DOI: 10.1007/s00213-019-05412-y (opens in new tab) Full text (opens in new tab) 3-meo-pcmo 4-meo-pcp Abuse potential Dopaminergic system +2

Therapeutic potential of ayahuasca in grief: a prospective, observational study

Psychopharmacology January 14, 2020 Débora González, Jordi Cantillo, Irene Hidalgo Pérez et al. 73 citations

Abstract Rationale Recent studies have assessed the therapeutic potential of ayahuasca for the treatment of depression with promising preliminary results . Objectives Here, we examine the course of grief over 1 year of follow-up in a bereaved sample that attended a center in Peru to participate in indigenous Shipibo ayahuasca ceremonies. We also explore the roles of experiential avoidance and...

Ayahuasca’s ‘afterglow’: improved mindfulness and cognitive flexibility in ayahuasca drinkers

Psychopharmacology January 11, 2020 Ashleigh Murphy-Beiner, Kirstie Soar 142 citations

The present study supports ayahuasca's ability to enhance mindfulness and further reports changes in cognitive flexibility in the 'afterglow' period occur, suggesting both could be possible psychological mechanisms concerning the psychotherapeutic effects of ayahuasca. Given psychological gains occurred regardless of prior ayahuasca use suggests potentially therapeutic effects for both naïve...

Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers

Psychopharmacology December 18, 2019 Neiloufar Family, Émeline L. Maillet, Luke T. J. Williams et al. 142 citations

Abstract Abstract Research has shown that psychedelics, such as lysergic acid diethylamide (LSD), have profound anti-inflammatory properties mediated by 5-HT 2A receptor signaling, supporting their evaluation as a therapeutic for neuroinflammation associated with neurodegenerative disease. Objective This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally...

Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment

Psychopharmacology December 10, 2019 Malin V. Uthaug, Rafael Lancelotta, Attila Szabo et al. 116 citations

Abstract Rationale 5-methoxy-N,N-dimethyltryptamine is a psychotropic substance found in various plant and animal species and is synthetically produced. 5-methoxy-N,N-dimethyltryptamine is used in naturalistic settings for spiritual exploration, recreation, or to address negative affect and mood problems. However, scientific knowledge on the effects of 5- methoxy-N,N-dimethyltryptamine in...

Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics

Psychopharmacology November 29, 2019 Sam G. Moreton, Luke Szalla, Rachel E. Menzies et al. 77 citations

Psychedelic therapies can engender enduring improvements in psychological well-being. However, relatively little is known about the psychological mechanisms through which the salutary effects of psychedelics emerge. Through integrating extant research on psychedelics with contemporary existential psychology, we present a novel hypothesis that reduced death anxiety may be a key mechanism...

Locomotor effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in mice: psychostimulant effects, stereotypy, and sensitization

Psychopharmacology November 15, 2019 Michael D. Berquist, Sebastian Leth-Petersen, Jesper L. Kristensen et al.

There is a renewed interest in the use of 3,4-methylenedioxymethamphetamine (MDMA) for treating psychiatric conditions. Although MDMA has entered phase II clinical trials and shows promise as an adjunct treatment, there is an extensive literature detailing the potential neurotoxicity and adverse neurobehavioral effects associated with MDMA use. Previous research indicates that the adverse...

Replication and extension of a model predicting response to psilocybin.

Psychopharmacology November 1, 2019 Suzanne L. Russ, R L Carhart-Harris, Geoffrey Maruyama et al. 75 citations

Recent research demonstrated the potential of psychedelic drugs as treatment for depression and death-related anxiety and as an enhancement for well-being. While generally positive, responses to psychedelic drugs can vary according to traits, setting, and mental state (set) before and during ingestion. Most earlier models explain minimal response variation, primarily related to dosage and...

MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.

Psychopharmacology September 1, 2019 Michael C Mithoefer, Allison A. Feduccia, Lisa Jerome et al. 364 citations Retracted

Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options. Here we evaluate six phase 2 trials in a pooled analysis to determine the study design for phase 3 trials of MDMA-assisted psychotherapy for PTSD. Six randomized, double-blind, controlled clinical trials at five study sites were conducted...

DOI: 10.1007/s00213-019-05249-5 (opens in new tab) Full text (opens in new tab) MDMA-Assisted Psychotherapy Posttraumatic stress disorder MDMA Alongside Therapy Active MDMA +7

Effects of haloperidol on the delta-9-tetrahydrocannabinol response in humans: a responder analysis.

Psychopharmacology September 1, 2019 Swapnil Gupta, Joao P De Aquino, Deepak C D'Souza et al.

Δ-9-Tetrahydrocannabinol (Δ-9-THC) produces psychotomimetic effects in humans. However, the role of dopamine signaling in producing such effects is unclear. We hypothesized that dopaminergic antagonism would reduce the psychotomimetic effect of Δ-9-THC. The objective of this study was to evaluate whether pre-treatment with haloperidol would alter the psychotomimetic and perceptual-altering...

DOI: 10.1007/s00213-019-05235-x (opens in new tab) Full text (opens in new tab) Antipsychotic Cannabinoid Dopamine Haloperidol +1

Effects of the synthetic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) on ethanol consumption and place conditioning in male mice

Psychopharmacology July 15, 2019 Aboagyewaah Oppong‐Damoah, Kristen Curry, Bruce E. Blough et al.

Approximately 20 million adults in the USA have an alcohol use disorder (AUD). There are clinical and preclinical data suggesting that psychedelics may have benefits for AUD. To investigate the effects of the synthetic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) on the behavioral effects of ethanol. The effects of DOI were examined using ethanol-induced place conditioning (1.8 g/kg...

Effects of the synthetic cannabinoid 5F-AMB on anxiety and recognition memory in mice.

Psychopharmacology July 1, 2019 Shiho Ito, Satoshi Deyama, Masaki Domoto et al.

N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine methyl ester (5F-AMB) is a synthetic cannabinoid that has been distributed recently. Although inhalation of 5F-AMB produces adverse effects, such as impaired memory and disturbed consciousness, in humans, the psychopharmacological effects of 5F-AMB in rodents have not been investigated. We first examined the effects of intraperitoneal...

DOI: 10.1007/s00213-019-05222-2 (opens in new tab) Full text (opens in new tab) 5f-amb Designer drug Medial prefrontal cortex Synthetic cannabinoids

False memory formation in cannabis users: a field study

Psychopharmacology June 27, 2019 Lilian Kloft, Henry Otgaar, Arjan Blokland et al. 19 citations

RATIONALE: Cannabis use is widespread and has previously been associated with memory impairments. However, the role of cannabis in relation to false memory production, i.e., memories of events that were not experienced, is less well-understood. OBJECTIVE: The aim of the current field study was to examine the impact of cannabis use on false memory production. METHODS: The...

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition

Psychopharmacology May 1, 2019 Thomas R. Arkell, Nicholas Lintzeris, Richard C. Kevin et al. 177 citations

BACKGROUND: The main psychoactive component of cannabis, delta-9-tetrahydrocannabinol (THC), can impair driving performance. Cannabidiol (CBD), a non-intoxicating cannabis component, is thought to mitigate certain adverse effects of THC. It is possible then that cannabis containing equivalent CBD and THC will differentially affect driving and cognition relative to THC-dominant cannabis. AIMS:...